SIGA Technologies reported a strong second quarter in 2022, marked by increased revenues driven by initial sales of oral TPOXX to the Asia-Pacific region and the U.S. Department of Defense, alongside ongoing international orders.
Total revenue increased to $16.7 million compared to $8.7 million in Q2 2021.
Operating income reached $3.1 million, a significant improvement from $0.0 million in Q2 2021.
Net income was reported at $2.0 million, up from $0.2 million in the same quarter last year.
Diluted income per share stood at $0.03, compared to $0.00 in Q2 2021.
SIGA Technologies anticipates a positive trend in the second half of 2022, driven by international orders for oral TPOXX, with deliveries expected through July 2023. The company expects $26 million of the $60 million in orders to be delivered in Q3 2022.
Visualization of income flow from segment revenue to net income